GO:0006154 adenosine catabolic process: Purine Salvage and Signaling, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006154 adenosine catabolic process describes the biochemical breakdown of adenosine, a ribonucleoside that is both a building block of nucleic acids and a potent signaling molecule.
• The pathway is essential for controlling intracellular adenosine levels, which directly influence sleep homeostasis, neuronal excitability, and cardiac function.
• Key enzymes include adenosine deaminase (ADA), adenosine kinase (ADK), purine nucleoside phosphorylase (PNP), and the recently characterized ADAL, which detoxifies modified adenosines.
• Dysregulation of adenosine catabolism is linked to epilepsy, cardiac hypertrophy, and metabolic disorders, making it a target for therapeutic intervention.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of enzyme function and pathway flux in disease-relevant cell types.
• Understanding adenosine catabolism supports research in neurobiology, immunology, and cancer biology, where adenosine signaling shapes the tumor microenvironment and immune responses.
Description
Adenosine is a ubiquitous ribonucleoside that serves dual roles as a structural component of nucleic acids and as a signaling molecule regulating diverse physiological processes. The controlled breakdown of adenosine, defined by the Gene Ontology term GO:0006154 adenosine catabolic process, is therefore critical for maintaining cellular homeostasis and preventing the accumulation of potentially toxic metabolites. This catabolic process ensures that adenosine levels are kept within a narrow physiological range, as excessive adenosine can lead to profound effects on neuronal activity, cardiac function, and immune cell behavior. Research into adenosine catabolism has gained momentum because of its implications in human disease. For instance, mutations or altered expression of enzymes such as adenosine deaminase (ADA) and adenosine kinase (ADK) have been associated with severe combined immunodeficiency, epilepsy, and cardiac hypertrophy. Moreover, the discovery of ADAL, an enzyme that detoxifies modified adenosines, highlights the expanding complexity of this pathway and its role in safeguarding cellular metabolism. Understanding the molecular players and regulatory mechanisms of adenosine catabolic process is thus essential for developing targeted therapies. This article provides a comprehensive overview of GO:0006154, integrating authoritative QuickGO annotations with verified PubMed literature. We cover the definition, key genes, regulatory aspects, disease associations, and state-of-the-art research methods, including CRISPR-based models. By focusing on experimentally validated findings, we aim to equip researchers with a reliable resource for studying adenosine catabolism in health and disease.
adenosine catabolic process At A Glance
| GO ID | GO:0006154 |
|---|---|
| GO term | adenosine catabolic process |
| Ontology | biological_process |
| Synonym | adenosine breakdown, adenosine catabolism, adenosine degradation, adenosine phosphorolysis |
| Major function | Breakdown of adenosine to regulate its intracellular and extracellular levels, preventing toxicity and modulating signaling |
| Key enzymes | ADA, ADK, PNP, ADAL, and other nucleoside-metabolizing enzymes |
| Pathway context | Purine metabolism; adenosine salvage and degradation intersect with nucleic acid turnover and energy metabolism |
| Disease relevance | Epilepsy, cardiac hypertrophy, immunodeficiency, and metabolic disorders |
| Research methods | CRISPR knockout/knock-in, RNA-seq, metabolomics, enzyme assays, and animal models |
What Is GO:0006154?
The adenosine catabolic process (GO:0006154) encompasses the chemical reactions and pathways that result in the breakdown of adenosine, a ribonucleoside composed of adenine and ribose. This process includes enzymatic steps that convert adenosine into downstream metabolites such as inosine, adenine, and eventually uric acid, thereby regulating the intracellular and extracellular concentrations of this signaling molecule. The term is synonymous with adenosine breakdown, adenosine catabolism, adenosine degradation, and adenosine phosphorolysis, reflecting the diversity of biochemical routes that cells employ to catabolize adenosine.
Why Is adenosine catabolic process Important in Cell Biology?
Adenosine catabolic process is fundamentally important because adenosine is not only a building block for RNA and DNA but also a critical signaling molecule that modulates neuronal activity, cardiac function, and immune responses. The breakdown of adenosine prevents its excessive accumulation, which can lead to receptor desensitization, altered sleep patterns, and pathological conditions such as epilepsy and cardiac hypertrophy. Furthermore, the catabolic pathway intersects with the metabolism of modified adenosines, such as N6-methyladenosine (m6A), and defects in enzymes like ADAL can cause metabolic stress and disease. Therefore, understanding how adenosine is catabolized provides insights into basic cell biology and offers therapeutic avenues for a range of disorders.
• Regulates adenosine levels to maintain sleep homeostasis and neuronal excitability.
• Prevents adenosine toxicity and supports cardiac function; METTL3-mediated m6A deposition and adenosine metabolism are linked to cardiac hypertrophy.
• Mutations in adenosine deaminase (ADA) cause severe combined immunodeficiency, highlighting the importance of adenosine catabolism in immune function.
• ADAL detoxifies modified adenosines, and its loss leads to metabolic dysfunction, linking catabolism to cellular stress responses.
• Adenosine catabolism influences epilepsy susceptibility; ADK and ADA are targets for seizure control.
• The pathway is relevant to cancer immunotherapy because adenosine suppresses anti-tumor immune responses.
• Enzymes of adenosine catabolism are potential drug targets for inflammatory and neurological diseases.
• CRISPR screens can identify novel regulators of adenosine catabolism, accelerating therapeutic discovery.
• Adenosine catabolism intersects with m6A RNA modification, connecting it to epitranscriptomic regulation.
• Understanding adenosine catabolism aids in interpreting metabolomic data and designing adenosine-associated delivery systems.
What Happens During adenosine catabolic process?
Deamination of adenosine to inosine
In simple terms: Adenosine is converted into inosine by removing an amino group.
The first step in one major route of adenosine catabolism is the deamination of adenosine to inosine, catalyzed by adenosine deaminase (ADA). This reaction is crucial for maintaining adenosine levels and preventing its accumulation. ADA deficiency leads to severe combined immunodeficiency due to toxic accumulation of adenosine and deoxyadenosine. The enzyme is widely expressed and its activity is tightly regulated to respond to metabolic demands.
Phosphorolysis of adenosine to adenine
In simple terms: Adenosine can be split into adenine and ribose-1-phosphate.
Alternatively, adenosine can undergo phosphorolysis to yield adenine and ribose-1-phosphate, a reaction catalyzed by purine nucleoside phosphorylase (PNP). This pathway is particularly important in purine salvage and is essential for maintaining nucleotide pools. Deficiencies in PNP cause immunodeficiency and neurological disorders, underscoring the importance of this catabolic step.
Phosphorylation and subsequent deamination
In simple terms: Adenosine is first converted to AMP, then to inosine monophosphate (IMP).
Adenosine can also be phosphorylated by adenosine kinase (ADK) to AMP, which then enters the purine degradation pathway via deamination to IMP. ADK is a key enzyme that regulates intracellular adenosine levels, and its inhibition increases adenosine, which can have neuroprotective effects. This route links adenosine catabolism to energy metabolism and nucleic acid turnover.
Detoxification of modified adenosines by ADAL
In simple terms: ADAL removes modified adenosines that could otherwise disrupt metabolism.
Recent studies have identified ADAL as an enzyme that detoxifies modified adenosines, such as N6-methyladenosine (m6A) and other methylated forms. ADAL coordinates with adenosine kinase to safeguard metabolism, and its loss leads to accumulation of modified adenosines, causing metabolic stress. This pathway highlights the expanding role of adenosine catabolism in handling RNA modifications and maintaining cellular health.
Regulation of adenosine catabolism by cellular signals
In simple terms: The breakdown of adenosine is adjusted based on the cell's needs.
Adenosine catabolism is regulated at multiple levels, including enzyme expression, post-translational modifications, and substrate availability. For example, hypoxia and inflammation can alter the expression of ADA and ADK, thereby affecting adenosine levels. The interplay between adenosine catabolism and signaling pathways such as the mTOR pathway is an area of active investigation, as adenosine levels influence cell growth and survival.
Key Genes Involved in GO:0006154 adenosine catabolic process
The following genes and proteins are central to the adenosine catabolic process, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADA | Catalyzes deamination of adenosine to inosine | Deficiency causes SCID; target for enzyme replacement therapy |
| ADK | Phosphorylates adenosine to AMP, regulating intracellular adenosine | Inhibition increases adenosine; implicated in epilepsy and neuroprotection |
| PNP | Catalyzes phosphorolysis of adenosine to adenine | Deficiency leads to immunodeficiency; target for purine metabolism studies |
| ADAL | Detoxifies modified adenosines (e.g., m6A) | Loss causes metabolic stress; links adenosine catabolism to epitranscriptomics |
| METTL3 | m6A methyltransferase; influences adenosine metabolism indirectly | Regulates cardiac homeostasis; crosstalk with adenosine catabolism |
| METTL14 | Component of m6A methyltransferase complex | Cooperates with METTL3; potential impact on adenosine metabolism |
| ADAR | RNA editing enzyme; adenosine to inosine editing | Engineered ADAR-recruiting RNAs enhance editing; relevance to adenosine catabolism |
| ENT1 | Equilibrative nucleoside transporter; regulates adenosine uptake | Modulates extracellular adenosine levels; drug target |
| ENT2 | Nucleoside transporter; facilitates adenosine transport | Influences adenosine availability for catabolism |
| CD73 | Ecto-5'-nucleotidase; converts AMP to adenosine | Regulates extracellular adenosine; immune suppression in tumors |
| CD39 | Ectonucleotidase; converts ATP/ADP to AMP | Works with CD73 to produce adenosine; target in inflammation |
| A2AR | Adenosine receptor A2A; mediates signaling | Modulates sleep and neuroprotection; interacts with catabolism |
| A1R | Adenosine receptor A1; inhibits neuronal activity | Involved in epilepsy; adenosine catabolism affects receptor activation |
| A2BR | Adenosine receptor A2B; involved in inflammation | Potential target in cancer and fibrosis |
| A3R | Adenosine receptor A3; modulates immune responses | Role in ischemia and inflammation |
| SAM | S-adenosylmethionine; methyl donor for m6A | Links methylation to adenosine metabolism |
| MTR | Methionine synthase; affects SAM levels | Indirectly influences adenosine modification and catabolism |
How Is adenosine catabolic process Regulated?
Adenosine catabolic process is regulated at multiple levels to meet cellular demands. Enzyme expression is controlled by transcription factors responsive to hypoxia, inflammation, and metabolic stress. For instance, hypoxia-inducible factors (HIFs) can upregulate CD73 and CD39, increasing extracellular adenosine production and subsequent catabolism. Post-translational modifications, such as phosphorylation, modulate the activity of ADA and ADK. Additionally, substrate availability and feedback inhibition by downstream metabolites influence flux through the pathway. The interplay between adenosine catabolism and m6A RNA methylation is emerging as a regulatory node, with METTL3 and ADAL coordinating to prevent toxic accumulation of modified adenosines. Furthermore, adenosine receptor signaling can feedback to regulate catabolic enzymes, creating a homeostatic loop.
adenosine catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADA | Severe combined immunodeficiency (SCID) | ADA knockout mice; patient-derived iPSCs |
| ADK | Epilepsy | ADK transgenic mice; neuronal cultures |
| METTL3 | Cardiac hypertrophy and heart failure | Cardiac-specific METTL3 knockout mice |
| ADAL | Metabolic stress; accumulation of modified adenosines | ADAL knockout cell lines; metabolomics |
| PNP | Immunodeficiency | PNP knockout mice; lymphocyte cultures |
Adenosine catabolism in epilepsy
Epilepsy is characterized by neuronal hyperexcitability, and adenosine acts as an endogenous anticonvulsant. Dysregulation of adenosine catabolism, particularly altered expression of ADK and ADA, has been observed in epileptic tissue. Increased ADK activity lowers adenosine levels, promoting seizures, while ADA deficiency elevates adenosine, which can be protective. Targeting adenosine catabolic enzymes is therefore a potential therapeutic strategy for epilepsy.
Cardiac hypertrophy and heart failure
METTL3, an m6A methyltransferase, controls cardiac homeostasis and hypertrophy, and its loss leads to heart failure in mice. Adenosine metabolism is intertwined with m6A modification, as ADAL detoxifies m6A and other modified adenosines. Thus, dysregulation of adenosine catabolism may contribute to cardiac pathology by affecting RNA modification and energy balance.
Immunodeficiency and immune regulation
Deficiency of ADA causes severe combined immunodeficiency (SCID) due to accumulation of toxic adenosine and deoxyadenosine metabolites that impair lymphocyte development. Similarly, PNP deficiency leads to immunodeficiency. These disorders highlight the critical role of adenosine catabolism in immune cell function and survival.
Cancer and the tumor microenvironment
Adenosine suppresses anti-tumor immune responses, and enzymes like CD73 and CD39 that generate adenosine are often overexpressed in tumors. Catabolism of adenosine by ADA can reduce its immunosuppressive effects, making ADA a potential target for cancer immunotherapy. Understanding adenosine catabolism in the tumor microenvironment is therefore of great clinical interest.
From adenosine catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADA affect adenosine levels and immune cell development? | ADA knockout mice or human iPSC-derived lymphocytes |
| How does ADK inhibition impact seizure susceptibility? | ADK knockout or point-mutation mice; EEG monitoring |
| What is the role of METTL3 in cardiac hypertrophy? | Cardiac-specific METTL3 knockout mice |
| Can ADAL detoxify m6A and prevent metabolic stress? | ADAL overexpression or knockout cell lines; metabolomics |
| How does adenosine catabolism influence sleep homeostasis? | Conditional knockout of adenosine receptors or enzymes in mice; sleep recordings |
| What are the effects of adenosine receptor modulation on inflammation? | A2AR or A2BR knockout mice; inflammation models |
How to Study the adenosine catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of adenosine and catabolites | Quantifying pathway flux in cells and tissues |
| Enzyme activity assay | Catalytic activity of ADA, ADK, PNP | Kinetic studies and inhibitor screening |
| CRISPR knockout screen | Genes affecting adenosine sensitivity | Discovery of novel regulators |
| MeRIP-seq | m6A modification sites on RNA | Linking adenosine catabolism to epitranscriptomics |
| RNA-seq | Transcriptional changes upon pathway perturbation | Identifying compensatory mechanisms |
| EEG telemetry | Seizure activity in vivo | Evaluating ADK or ADA modulation in epilepsy models |
| Sleep recordings | Sleep-wake architecture | Assessing adenosine catabolism in sleep homeostasis |
| Cardiac function tests | Heart function and hypertrophy | Studying METTL3 and adenosine metabolism in heart |
Metabolomics and enzyme assays
Mass spectrometry-based metabolomics allows quantification of adenosine and its catabolites (inosine, adenine, AMP, IMP) in cells and tissues. Enzyme activity assays using recombinant ADA, ADK, or PNP provide kinetic parameters and inhibitor profiles. These methods are essential for assessing pathway flux and identifying metabolic bottlenecks.
CRISPR screens and functional genomics
Genome-wide CRISPR knockout screens can identify genes that regulate adenosine catabolism or mediate sensitivity to adenosine analogs. For example, screens in cancer cell lines have revealed roles for ADAL and METTL3 in adenosine metabolism. Such screens are powerful for discovering novel pathway components and therapeutic targets.
RNA-seq and epitranscriptomic profiling
RNA sequencing and m6A-specific approaches (MeRIP-seq) can reveal how adenosine catabolism intersects with RNA modification. METTL3 and METTL14 are core m6A writers, and their manipulation affects adenosine-related pathways. These methods help uncover crosstalk between adenosine catabolism and gene expression regulation.
Animal models and behavioral assays
Mouse models with genetic alterations in adenosine catabolic enzymes (e.g., ADA, ADK, METTL3) are used to study epilepsy, sleep, and cardiac function. Behavioral assays such as EEG, sleep recordings, and cardiac function tests provide physiological readouts. These models are critical for translating molecular findings to whole-organism physiology.
How CRISPR Can Be Used to Study GO:0006154 adenosine catabolic process
Knockout
CRISPR knockout of genes such as ADA, ADK, PNP, or ADAL allows researchers to assess their essentiality in adenosine catabolism. For example, ADA knockout cells accumulate adenosine and deoxyadenosine, mimicking SCID phenotypes. ADK knockout mice exhibit increased adenosine levels and reduced seizure susceptibility. These models are invaluable for dissecting pathway function and identifying compensatory mechanisms.
Point Mutation
Introducing point mutations in catalytic residues of adenosine catabolic enzymes (e.g., ADA, ADK) can separate enzymatic activity from non-catalytic functions. For instance, mutation of the catalytic site of ADAL abolishes its detoxification activity, leading to metabolic stress. Such models help define the precise contribution of enzymatic activity to cellular phenotypes.
Knock-in
Knock-in of tagged or fluorescently labeled enzymes (e.g., ADA-GFP, ADK-FLAG) enables real-time tracking of protein localization and interactions. Knock-in of disease-associated mutations (e.g., ADA mutations found in SCID patients) can model human pathology in cell lines or mice. These approaches provide insights into protein dynamics and disease mechanisms.
Overexpression
Overexpression of adenosine catabolic enzymes (e.g., ADA, ADAL) can reduce adenosine levels and modulate signaling. For example, ADAL overexpression protects cells from modified adenosine toxicity. Overexpression models are useful for gain-of-function studies and for testing therapeutic hypotheses.
How EDITGENE Supports adenosine catabolic process Research
Researchers studying adenosine catabolic process-related genes often need to determine whether a candidate gene is causally involved in pathway regulation, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models, as well as high-throughput library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for adenosine catabolic process research.
Frequently Asked Questions About adenosine catabolic process
What is adenosine catabolic process?
Adenosine catabolic process (GO:0006154) is the set of biochemical reactions that break down adenosine into metabolites such as inosine and adenine, regulating its cellular levels.
What genes are involved in adenosine catabolic process?
Key genes include ADA, ADK, PNP, and ADAL, which encode enzymes that catalyze different steps of adenosine breakdown.
How is adenosine catabolic process regulated?
It is regulated by enzyme expression, post-translational modifications, substrate availability, and feedback from adenosine receptors and cellular stress pathways.
Why is adenosine catabolism important for the brain?
Adenosine modulates neuronal excitability and sleep; its catabolism prevents excessive adenosine buildup that could disrupt signaling.
What diseases are linked to adenosine catabolic process?
Defects in this pathway are associated with severe combined immunodeficiency, epilepsy, cardiac hypertrophy, and cancer immune evasion.
How can CRISPR be used to study adenosine catabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes like ADA, ADK, and ADAL to study their function in adenosine catabolism.
What is the role of ADAL in adenosine catabolism?
ADAL detoxifies modified adenosines such as m6A, preventing metabolic stress and coordinating with adenosine kinase.
How does METTL3 relate to adenosine catabolism?
METTL3 deposits m6A on RNA, and its activity intersects with adenosine catabolism because modified adenosines are substrates for detoxification by ADAL.
What methods are used to study adenosine catabolic process?
Common methods include metabolomics, enzyme activity assays, CRISPR screens, RNA-seq, and animal models such as EEG and sleep recordings.
Can adenosine catabolism be targeted for therapy?
Yes, enzymes like ADA, ADK, and CD73 are being explored as drug targets for epilepsy, cancer, and inflammatory diseases.
Conclusion
The adenosine catabolic process (GO:0006154) is a fundamental biochemical pathway that controls adenosine levels and thereby influences a wide range of physiological and pathological processes. From immune function to neuronal excitability and cardiac health, the enzymes that catabolize adenosine are critical regulators. Advances in CRISPR-based models and metabolomic technologies are accelerating our understanding of this pathway and its therapeutic potential. Continued research into adenosine catabolism promises to yield new insights and treatments for diseases such as epilepsy, immunodeficiency, and cancer.
References
- 1. Ogawa A et al.. 2025. Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolism.. Cell 188(22):6151-6169.e24 PMID: 40840445
- 2. Wang P et al.. 2016. Structural Basis for Cooperative Function of Mettl3 and Mettl14 Methyltransferases.. Mol Cell 63(2):306-317 PMID: 27373337
- 3. Yi Z et al.. 2022. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo.. Nat Biotechnol 40(6):946-955 PMID: 35145313
- 4. Weltha L et al.. 2019. The role of adenosine in epilepsy.. Brain Res Bull 151:46-54 PMID: 30468847
- 5. Kazemzadeh-Narbat M et al.. 2015. Adenosine-associated delivery systems.. J Drug Target 23(7-8):580-96 PMID: 26453156
- 6. Dorn LE et al.. 2019. The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy.. Circulation 139(4):533-545 PMID: 30586742
- 7. Camici M et al.. 2018. The Inside Story of Adenosine.. Int J Mol Sci 19(3) PMID: 29522447
- 8. Greene RW et al.. 2017. The adenosine-mediated, neuronal-glial, homeostatic sleep response.. Curr Opin Neurobiol 44:236-242 PMID: 28633050
